Loading…
Aclarion, Inc. is projected to rise to $2.57 by 2027, a +9% move from its current price of $2.36. ACON is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.28 | $2.36 | $2.44 | 0.00% |
| Aug 6 | $2.25 | $2.36 | $2.48 | 0.00% |
| Aug 7 | $2.22 | $2.36 | $2.51 | +0.01% |
| Aug 8 | $2.20 | $2.36 | $2.53 | +0.01% |
| Aug 9 | $2.18 | $2.36 | $2.55 | +0.01% |
| Aug 10 | $2.16 | $2.36 | $2.57 | +0.01% |
| Aug 11 | $2.15 | $2.36 | $2.59 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.15 | $2.36 | $2.59 | +0.01% |
| Week 2 | $2.07 | $2.36 | $2.69 | +0.03% |
| Week 3 | $2.01 | $2.36 | $2.78 | +0.04% |
| Week 4 | $1.96 | $2.36 | $2.85 | +0.06% |
| Week 5 | $1.92 | $2.36 | $2.91 | +0.07% |
| Week 6 | $1.88 | $2.36 | $2.97 | +0.09% |
| Week 7 | $1.85 | $2.36 | $3.02 | +0.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments.
The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also offers NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient.
Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado. It was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
The asset trades as Aclarion, Inc. (ACON) with current price $2.25 and a market cap of $5.54M, ranking #5253 by market capitalization. The business is categorized in Healthcare. The current price is supported by a multi-year forecast that shows a flat to modest start in the coming years and a transition to higher price levels in later years, including a 2040 average around $4.37 and a 2050 average around $5.55.
The stock exhibits high volatility (annualized volatility 70%) and a bearish near-term tone as reflected in the technicals. The forecast indicates mixed momentum through 2029, turning bullish in the 2030s and beyond, with potential upside in the long run.
A major floor 42.5% below — a decisive break under it would weaken the trend.
The nearest floor, 14.6% below — buyers have tended to step in here.
The nearest ceiling, 32.2% above — a clean break opens room to run.
A major ceiling 58.1% above — clearing it would confirm fresh momentum.
Key ACON support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACON market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.13 | Buy | $2.18 | Buy |
| MA 10 | $2.32 | Buy | $2.30 | Buy |
| MA 20 | $2.56 | Sell | $2.49 | Sell |
| MA 50 | $2.91 | Sell | $2.80 | Sell |
| MA 100 | $3.11 | Sell | $4.15 | Sell |
| MA 200 | $4.19 | Sell | $176.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.59 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -84.47 | Neutral |
| Williams %R (14) | -64.12 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -15.41 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 35.88 | Neutral |
| TRIX (15) | -0.95 | Sell |
| Awesome (5,34) | -0.60 | Sell |
| Ultimate (7,14,28) | 30.15 | Neutral |
| Momentum (10) | -0.33 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.98 | Buy |
| ADX (14) | 34.64 | Sell |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bearish with RSI(14) at 30. The 50-day simple moving average sits at $2.91, while the 200-day simple moving average is $4.19, indicating a longer-term downtrend. Support is at $2.02 and resistance at $3.12, framing a 30-day trading range from $1.78 to $2.84.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.02 | $2.36 | $3.07 | 0% | Neutral | |
| $1.99 | $2.57 | $3.52 | +9% | Neutral | |
| $1.99 | $2.66 | $3.83 | +13% | Neutral | |
| $1.84 | $2.54 | $3.79 | +8% | Neutral | |
| $1.53 | $2.17 | $3.34 | -8% | Neutral | |
| $1.67 | $2.43 | $3.84 | +3% | Neutral | |
| $1.86 | $2.77 | $4.47 | +17% | Neutral | |
| $1.95 | $2.98 | $4.91 | +26% | Bullish | |
| $2.14 | $3.33 | $5.60 | +41% | Bullish | |
| $1.97 | $3.14 | $5.37 | +33% | Bullish | |
| $2.62 | $4.58 | $8.44 | +94% | Bullish | |
| $2.81 | $5.83 | $11.94 | +147% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.02 | $2.36 | $2.89 | +0.00% |
| September 2026 | $1.95 | $2.32 | $2.86 | -1.63% |
| October 2026 | $1.97 | $2.36 | $2.95 | +1.85% |
| November 2026 | $2.02 | $2.45 | $3.09 | +3.49% |
| December 2026 | $1.97 | $2.40 | $3.07 | -1.77% |
Click any year to see its month-by-month ACON forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aclarion, Inc.'s 2026 outlook centres on $2.36, within a $2.02 to $3.07 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ACON could reach as high as $3.52, with a base case around $2.57 and support toward $1.99 — roughly +9% from $2.36. A consolidation phase looks the most probable path here.
Expect ACON to range from $1.99 to $3.83 through 2028. The $2.66 average target implies a +13% move from current prices. That is up +4% on the projected 2027 average. Price action looks broadly range-bound.
The ACON price prediction for 2029 points to an average of $2.54 (low $1.84, high $3.79) — a potential gain of +8% on today's $2.36. A consolidation phase looks the most probable path here.
In 2030, ACON is projected to trade between $1.53 and $3.34, averaging $2.17 — a potential decline of -8% from today's $2.36. That is -14% versus the projected 2029 average. Price action looks broadly range-bound.
Aclarion, Inc.'s 2031 outlook centres on $2.43, within a $1.67 to $3.84 range. That is up +12% on the projected 2030 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, ACON could reach as high as $4.47, with a base case around $2.77 and support toward $1.86 — roughly +17% from $2.36. Price action looks broadly range-bound.
Expect ACON to range from $1.95 to $4.91 through 2033. The $2.98 average target implies a +26% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ACON price prediction for 2034 points to an average of $3.33 (low $2.14, high $5.60) — a potential gain of +41% on today's $2.36. Momentum favours further upside here.
In 2035, ACON is projected to trade between $1.97 and $5.37, averaging $3.14 — a potential gain of +33% from today's $2.36. That is -6% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Aclarion, Inc.'s 2040 outlook centres on $4.58, within a $2.62 to $8.44 range. That is up +46% on the projected 2035 average. That marks a +94% change versus current levels. Momentum favours further upside here.
By 2050, ACON could reach as high as $11.94, with a base case around $5.83 and support toward $2.81 — roughly +147% from $2.36. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACON today (≈ 423.728814 ACON) could be worth
$2,470.43
+$1,470.43 (+147%) by 2050 · US Dollar
Based on the average projected ACON price of $5.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACONwould be worth at today's price.
$1,000 invested in ACON on Jul 31, 2025 (≈ 143.884896 ACON) would be worth
$339.57
-$660.43 (-66.0%) today · 0.34× · US Dollar
Based on a ACON entry price of $6.95 vs. today's $2.36.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.42 | $975.21 | -2.5% |
| 1 month ago | $3.02 | $781.46 | -21.9% |
| 3 months ago | $3.42 | $690.06 | -31.0% |
| 6 months ago | $2.88 | $819.44 | -18.1% |
| 1 year ago | $6.95 | $339.57 | -66.0% |
| All time (4.3y) ago | $393,638.41 | $0.01 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACON forecast.
Our base-case forecast reaches $4.70 around 2050.
Implied market cap at $4.70: $11.57M
Forecasts by year show a path from muted near-term performance to a stronger longer-term upturn. In 2026 the average is $2.25 with 0.0% ROI, and in 2027 the average rises to $2.45 with an 8.9% ROI, followed by 2028 with $2.53 and 12.7% ROI, and 2029 with $2.41 and 7.3% ROI. The 2030 projection is $2.07 average with a -7.9% ROI.
In 2033 the average climbs to $2.84 with a 26.3% ROI, and 2034 to $3.18 with 41.3%. In 2035 the average is $2.99 with 33.0% ROI. The later horizon shows stronger upside: 2040 average $4.37 with 94.3% ROI and 2050 average $5.55 with 146.8% ROI.
These are estimates, not guarantees, and reflect a trajectory of higher potential in the long run but with continued volatility and uncertainty.
Tap a question to reveal the answer.
Avg $2.07, min $1.46, max $3.19; ROI -7.9%; sentiment NEUTRAL.
Forecast shows mixed potential: near term is neutral to slightly positive in early years, with a negative ROI in 2030 (-7.9%), followed by stronger upside in later years (e.g., 2040 ROI 94.3%, 2050 ROI 146.8%). The max forecast reaches $11.38 by 2050, with the 2050 average $5.55.
Yes. The forecast shows a 2034 max of $5.35, a 2040 max of $8.06, and a 2050 max of $11.38, indicating that reaching and exceeding $5 is within the projected range.
Current price is $2.25 and market cap is $5.54M.
RSI(14) is 30 (bearish); SMA(50) is $2.91; SMA(200) is $4.19. Support is at $2.02 and resistance at $3.12, with a 30-day range from $1.78 to $2.84.
Aclarion, Inc. Community Discussion
0Share your Aclarion, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.